This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Walgreens Boots Alliance (WBA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed at $46.08 in the latest trading session, marking a +0.39% move from the prior day.
Walgreens Boots Alliance (WBA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $47.32, moving +0.72% from the previous trading session.
Walgreens (WBA) to Offer COVID-19 Vaccine Booster Shots
by Zacks Equity Research
Individuals aged 18 years or older are eligible to avail Pfizer, Moderna or Johnson & Johnson COVID-19 vaccine boosters from Walgreens' (WBA) stores.
Walgreens Boots Alliance (WBA) Stock Moves -0.65%: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed at $49.22 in the latest trading session, marking a -0.65% move from the prior day.
Walgreens (WBA), VillageMD Plan to Expand Into Tampa, Florida
by Zacks Equity Research
Walgreens (WBA), VillageMD to open 20 new Village Medical at Walgreens primary care practices in the Tampa area to improve access to overall care for patients with chronic conditions.
Here's Why You Should Hold on to Walgreens Boots (WBA) for Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) given its better-than-expected fourth-quarter fiscal 2021 results and strategic alliances.
Walgreens (WBA) to Make Additional Investment in VillageMD
by Zacks Equity Research
Walgreens (WBA) announced a $5.2-billion investment in VillageMD to bolster its strategic position in delivering value-based primary care.
Ride the Latest Market Rally With These ETFs
by Sweta Jaiswal, FRM
The third-quarter earnings season has begun with a bang, spreading optimism among investors.
NextGen's (NXGN) Integrated Platform Gets Leveraged by Mednax
by Zacks Equity Research
Mednax utilizes NextGen's (NXGN) fully-integrated platform to enhance its efficacy in placing crucial information on patients' health and well-being at the physician's fingertips.
Stock Market News for Oct 15, 2021
by Zacks Equity Research
U.S. stocks ended sharply higher on Thursday after upbeat earnings and better-than expected economic data gave a boost to investors¿¿¿ confidence.
Walgreens (WBA) Hits 300M Milestone With Vitamin Angels
by Zacks Equity Research
Walgreens (WBA) and Vitamin Angels are looking to hit a new goal of reaching 500 million women and children by the end of August 2025.
Walgreens Boots (WBA) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Walgreens Boots' (WBA) health and wellness sales increase for fiscal Q4 on growing demand for at-home COVID-19 tests and vitamins.
Walgreens Boots Alliance (WBA) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Walgreens (WBA) delivered earnings and revenue surprises of 13.59% and 2.96%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Walgreens (WBA) Ahead of Earnings?
by Zacks Equity Research
Walgreens (WBA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Commercial Metals' (CMC) Q4 Earnings?
by Zacks Equity Research
Commercial Metals' (CMC) Q4 results likely to reflect strong finished steel volumes, driven by solid construction and infrastructure demand.
Walgreens Boots Alliance (WBA) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Walgreens (WBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Walgreens (WBA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Faster adoption of digital health and an improved business environment are expected to have contributed to Walgreens' (WBA) fourth-quarter performance.
Here's How Investors Can Find Strong Retail and Wholesale Stocks with the Zacks ESP Screener
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Stock Market News for Oct 1, 2021
by Zacks Equity Research
Benchmarks closed in the red on Thursday despite Congress' last-minute move to prevent a partial government shutdown.
Walgreens Boots Alliance (WBA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $48.71, marking a +1.29% move from the previous day.
3 High-Potential MedTech Stocks With More Than 50% Growth YTD
by Riya Anand
Stocks like West Pharmaceuticals Services (WST), Maravai LifeSciences (MRVI) and Option Care Health (OPCH) have gained stupendously year to date.
Walgreens Boots Alliance (WBA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $48.46, marking a +0.94% move from the previous day.
Here's Why You Should Retain Walgreens (WBA) Stock for Now
by Zacks Equity Research
Investors are optimistic about Walgreens (WBA), given the strong performance in the International segment and notable product launches.
Rite Aid (RAD) to Report Q2 Earnings: What Should You Know?
by Zacks Equity Research
Rite Aid (RAD) is likely to have gained from PBM, RxEvolution strategy and expanded omnichannel services in Q2. Rising wage costs and drab front-end same-store sales are likely to have been concerns.
Walgreens Boots Alliance (WBA) Stock Moves -0.64%: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed the most recent trading day at $49.62, moving -0.64% from the previous trading session.